Enzalutamide

Malignant neoplasm of prostate, Malignant Neoplasms
Treatment
14 Active Studies for Enzalutamide

What is Enzalutamide

EnzalutamideThe Generic name of this drug
Treatment SummaryEnzalutamide is a medication used to treat prostate cancer that does not respond to other treatments. It works by blocking androgen receptors, which stops hormones from stimulating tumor growth. Enzalutamide was approved by the FDA in 2012 under the brand name Xtandi.
Xtandiis the brand name
image of different drug pills on a surface
Enzalutamide Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Xtandi
Enzalutamide
2012
5

Effectiveness

How Enzalutamide Affects PatientsEnzalutamide is a drug designed to stop prostate cancer from progressing. It does this by blocking the hormones and hormone receptors that cause prostate cells to grow. After a few years, prostate cancer will start to become resistant to hormone deprivation treatment, but studies show that Enzalutamide can help to slow the growth of prostate cancer cells. Clinical trials suggest that Enzalutamide can reduce the risk of death in patients by 37% compared to those taking a placebo. The drug also reduces serum PSA levels for at least 12 weeks, although this effect may be short-lived.
How Enzalutamide works in the bodyEnzalutamide is a drug that blocks the effects of testosterone and other male hormones on cancer cells. It prevents testosterone and other hormones from binding to the androgen receptor, a protein that tells the cancer cell to grow and spread. Enzalutamide is more effective at blocking hormones from binding to the receptor than some other drugs, and it has fewer side effects. It also works better than testosterone at preventing cancer cells from growing and spreading.

When to interrupt dosage

The recommended amount of Enzalutamide is contingent upon the diagnosed illness. The dose may also differ as per the administration approach (e.g. Capsule - Oral or Tablet - Oral) outlined in the table below.
Condition
Dosage
Administration
Malignant neoplasm of prostate
, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral
Malignant Neoplasms
, 40.0 mg, 80.0 mg
, Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Warnings

There are 20 known major drug interactions with Enzalutamide.
Common Enzalutamide Drug Interactions
Drug Name
Risk Level
Description
1,2-Benzodiazepine
Major
The metabolism of 1,2-Benzodiazepine can be increased when combined with Enzalutamide.
3,5-diiodothyropropionic acid
Major
The metabolism of 3,5-diiodothyropropionic acid can be increased when combined with Enzalutamide.
5-androstenedione
Major
The metabolism of 5-androstenedione can be increased when combined with Enzalutamide.
6-O-benzylguanine
Major
The metabolism of 6-O-benzylguanine can be increased when combined with Enzalutamide.
7-ethyl-10-hydroxycamptothecin
Major
The metabolism of 7-ethyl-10-hydroxycamptothecin can be increased when combined with Enzalutamide.
Enzalutamide Toxicity & Overdose RiskIn studies with mice, taking enzalutamide orally during pregnancy caused embryo-fetal death, resorptions, and changes in the distance between genitalia, as well as cleft palate and missing palatine bone when taken at the highest dose. Rats who were given a single oral dose of 30 mg/kg on the 14th day of gestation had a fetal concentration of enzalutamide that was about 0.3 times that found in the mother's plasma. Enzalutamide may also reduce fertility in males. The most common side effects reported in adults include fatigue, back pain, diarrhea, joint pain, fl
image of a doctor in a lab doing drug, clinical research

Enzalutamide Novel Uses: Which Conditions Have a Clinical Trial Featuring Enzalutamide?

There are 30 ongoing trials assessing the potential of Enzalutamide for Castration Treatment.
Condition
Clinical Trials
Trial Phases
Malignant neoplasm of prostate
12 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Early Phase 1
Malignant Neoplasms
2 Actively Recruiting
Phase 3, Phase 1

Enzalutamide Reviews: What are patients saying about Enzalutamide?

5Patient Review
11/21/2014
Enzalutamide for Metastatic Castration-Resistant Prostate Cancer
Really effective with only a few small side effects. The fatigue is the worst part, but it's worth it considering how well this works. It's also quite expensive though.
2.3Patient Review
4/22/2013
Enzalutamide for Metastatic Castration-Resistant Prostate Cancer
I didn't find this treatment very effective. My disease progressed and I developed new bony metastasis within the 3 months of taking it. It's well tolerated though, with the main side effects being hot flashes and constant nausea.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about enzalutamide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enzalutamide better than chemotherapy?

"In a study of men with metastatic prostate cancer who had not received chemotherapy, those who were treated with enzalutamide had a longer time until cancer progression or death, improved overall survival, and delayed the need for chemotherapy by a median of 17 months."

Answered by AI

Is enzalutamide a form of chemotherapy?

"Xtandi is not a chemotherapy drug. Although it is used to treat cancer, Xtandi is a type of hormone therapy that works by preventing prostate cancer cells from growing and spreading by blocking the action of a group of hormones called androgens."

Answered by AI

How effective is enzalutamide for prostate cancer?

"On average, men who were given enzalutamide lived about 29% longer than men who were given placebo."

Answered by AI

How long do you take enzalutamide for?

"Xtandi is typically taken until prostate cancer starts to progress or spread (metastasize). It can cause side effects or adverse events, so the patient may need to stop taking it at some point."

Answered by AI

What are the side effects of taking enzalutamide?

"If you're experiencing any of the following, you may be suffering from a lack of vitamin d: weakness, tiredness, joint pain, muscle weakness or stiffness, weight loss, loss of appetite, headache, and dizziness."

Answered by AI

Clinical Trials for Enzalutamide

Image of BAMF Health in Grand Rapids, United States.

AB001 for Prostate Cancer

18+
Male
Grand Rapids, MI
This study is designed to investigate the safety, tolerability, and effectiveness of a new treatment called AB001 in both 177Lu-PSMA naïve and 177Lu-PSMA experienced patients with advanced prostate cancer. AB001 targets a specific protein found on prostate cancer cells called prostate specific membrane antigen (PSMA) and delivers radioactive particles to kill the cancer cells. The primary goal of the study is to determine the safety profile of AB001 and how well patients tolerate the treatment. Researchers also aim to identify the best dose and schedule for further testing and clinical development. AB001 could be a promising treatment because it uses alpha particles, which are highly effective at damaging cancer cells while causing minimal harm to surrounding healthy tissue. This targeted approach is expected to result in fewer side effects compared to other types of radiation therapy. This Phase 1 study consists of two main parts: dose escalation and dose expansion. In the first part, researchers will test different doses of AB001 to find the safest and most effective dose. In the second part, the selected dose will be further evaluated to refine the treatment schedule and gather more data on its effectiveness and safety. The study aims to provide early data on the anti-tumour activity of AB001 and determine the best dose and treatment schedule for future trials. Researchers hope that AB001 will offer a new and effective treatment option for patients with advanced prostate cancer.
Phase 1
Recruiting
BAMF Health (+3 Sites)Margaret YuARTBIO Inc.
Have you considered Enzalutamide clinical trials? We made a collection of clinical trials featuring Enzalutamide, we think they might fit your search criteria.Go to Trials
Have you considered Enzalutamide clinical trials? We made a collection of clinical trials featuring Enzalutamide, we think they might fit your search criteria.Go to Trials
Image of Odette Cancer Centre in Toronto, Canada.

SABR for Prostate Cancer

18+
Male
Toronto, Canada
There is increasing worldwide interest in exploring stereotactic ablative body radiotherapy (SABR) for treating metastases in men with prostate cancer, including for the treatment of oligoprogressive metastases. The latter applies to a situation whereby patients with widespread metastases undergoing systemic therapy present with a solitary or a few metastatic tumors that progress, while all other metastases are stable or responding. The usual practice would be to change systemic therapy at this point, but another approach is to locally ablate the "rogue" metastases and continue the same systemic therapy. SABR used in this scenario may delay the need to switch to another line of systemic therapy and improve progression-free survival while patients stay on the same systemic therapy.
Recruiting
Has No Placebo
Odette Cancer Centre
Image of University of California - San Diego Moores Cancer Center in San Diego, United States.

Darolutamide vs Enzalutamide for Prostate Cancer

18+
Male
San Diego, CA
This is a prospective, randomized, open-label phase II study comparing cognitive outcomes between men with metastatic and non-metastatic castration resistant prostate cancer (CRPC) or metastatic hormone sensitive prostate cancer (HSPC). Approximately 132 patients will be enrolled. Eligible patients will be randomized in a 1:1 fashion to treatment with enzalutamide 160 mg orally daily or darolutamide 600 mg orally twice daily, in combination with standard LHRH agonist based treatment. Cognitive assessments will be performed using modules from Cambridge Neuropsychological Test Automated Battery (CANTAB) an internationally recognized software for assessing cognitive function and impairment.
Phase 2
Waitlist Available
University of California - San Diego Moores Cancer Center (+10 Sites)Evanthia Galanis, MDBayer
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security